icosapent ethyl,amr101
amarin pharma
['reduce-it', 'icosapent']
a subanalysis of the reduce-it trials presented by in patients with recent acs shows high benefit of icosapentil ethyl: 37% in primary outcome 36% in recurrent events no increase in bleeding #lasectelleva #acc2023 
Interventional cardiologist. Profesor Asociado @UniversidadMH. Cardiology, Hospital Universitario de San Juan Alicante @cardiosanjuan . Spain